Cold Plasma Market Size, Share & Industry Analysis, By Product Type (Cold Plasma Systems and Accessories), By Technology (Atmospheric Pressure Plasma Jet, Dielectric Barrier Discharge, and Others), By Application (Wound Healing, Infection Control & Sterilization, Dermatology & Aesthetic Medicine, Cancer, and Other), By End-User (Hospitals & Specialty Clinics, Academic & Research Institutes, and Others), and Regional Forecast, 2026-2034

The global cold plasma market size was valued at USD 161.7 million in 2025. The market is projected to grow from USD 182.8 million in 2026 to USD 498.0 million by 2034, exhibiting a CAGR of 13.3% during the forecast period.

Cold plasma systems are used to inactivate pathogens, modulate tissue microenvironments, and decontaminate surfaces or food items without the use of heat. In healthcare, approved devices are used for treating chronic wounds and dermatological conditions. The market expansion is attributed to the ability of cold plasma to inactivate pathogens, modify biological micro-environments, and sterilize surfaces without causing thermal damage. Moreover, cold plasma treatment maintains tissue and material integrity, making it suitable for chronic wound management, dermatology, infection control, and surface disinfection in clinical environments.

Leading companies in this market include terraplasma medical GmbH, ADTEC Plasma Technology Co., Ltd., Relyon Plasma GmbH, and Neoplas Tools GmbH. These companies are actively focusing on securing regulatory approvals, fostering strong collaborations with wound-care networks, and maintaining a track record of publishing real-world evidence that demonstrates clinical benefits in chronic wounds. Furthermore, robust product offerings, ongoing clinical validation, and the integration of new technologies into products help these players maintain a leading position in the global market. 

MARKET DYNAMICS

MARKET DRIVERS

Rising Focus on Infection Prevention and Improved Patient Outcomes to Accelerate Market Growth 

Hospitals and clinics are prioritizing infection control and safer treatment approaches, particularly following the increased emphasis on hygiene and patient safety in recent years. Cold plasma devices are being recognized for their potential role in reducing contamination risk in wound-care and dermatology settings. As healthcare facilities strive to minimize complications, re-admissions, and prolonged recovery times, interest in supportive tools like cold plasma is increasing. In addition, the increasing emphasis on faster healing, better patient comfort, and reduced dependency on antibiotics is encouraging clinicians to consider cold plasma as part of comprehensive care, particularly in high-volume wound and skin care centers.

• For instance, according to a study published by German biotech company Viromed Medical in May 2025, its cold plasma system is capable of providing 100% infection prevention against methicillin-resistant Staphylococcus aureus. 

MARKET RESTRAINTS

Lack of Standardization to Hinder Market Expansion

Despite growing adoption, the market faces protocol and standardization challenges across devices and clinical settings. Cold Atmospheric Plasma (CAP) systems differ in energy source, gas composition, plume characteristics, reactive species, and exposure duration, making it difficult to generate uniform clinical protocols or compare results across institutions. Moreover, hospitals often require high-quality clinical evidence and reproducible outcomes before embedding CAP into treatment algorithms, particularly for chronic wound care, where variability in wound etiology complicates clinical interpretation. 

MARKET OPPORTUNITIES

Development of Home-based Cold Plasma Instruments to Offer Substantial Growth Opportunities

The development and introduction of products that can be easily adopted at outpatient wound centers, community clinics, and homecare settings can offer a significant opportunity for the global cold plasma market growth. Many patients with chronic wounds or skin conditions require frequent treatment, which makes repeated clinic visits time-consuming and costly. Moreover, home-use devices allow these patients to receive care more comfortably and consistently, while still being guided by a doctor or nurse. This reduces the burden on hospitals and outpatient centers, and also improves patient convenience and treatment compliance. As home-health services and remote care models continue to grow, there is a rising demand for simple, lightweight, and safe systems that can be used without professional supervision. 

• For instance, in June 2025, hyped science GmbH announced the launch of PHLAS, a next-generation skincare technology that is incorporated with cold plasma. The device is specially designed for homecare settings. 

MARKET CHALLENGES

Reimbursement Variability and Operational Integration Complexity to Offer Considerable Challenges

Healthcare adoption is still moderated by reimbursement uncertainty and the need for workflow alignment across clinical teams. Cold plasma often requires repeated sessions, making reimbursement models and clinical scheduling central to economic feasibility. Without standardized clinical pathways, treatment plans may vary significantly between practitioners, slowing institutional adoption. Training requirements also extend beyond physicians to include nurses, wound-care specialists, and outpatient clinic staff.

COLD PLASMA MARKET TRENDS

Shift Toward Portable, Clinic-Friendly Devices and Broader Evidence Generation is a Key Trend

The cold plasma market is witnessing a trend of rising adoption of portable and ergonomic devices. Portability and ease of use support frequent sessions and integration into standard wound pathways. In addition, comparative and mechanistic studies and real-world data continue to build the clinical case by showing pathogen load reduction and wound-healing support, including in stubborn, biofilm-laden wounds.

• For instance, in May 2024, US Medical Innovations, LLC received FDA approval for its Canady Helios Cold Plasma ablation system.

Download Free sample to learn more about this report.

Segmentation Analysis

By Product Type 

Cold Plasma Systems Led Market Due to Their Greater Safety 

By product type, the market is divided into cold plasma systems and accessories.

The cold plasma systems segment held the highest global cold plasma market share in 2025. The major share of the segment is attributed to the adoption of these systems as the primary treatment platform, which is used across hospitals, wound care centers, and dermatology clinics. Moreover, healthcare providers prefer purchasing complete systems first, as they enable routine procedures and can be integrated into existing care workflows. As awareness increases and more clinics incorporate cold plasma into their wound management protocols, demand for comprehensive systems continues to rise.

• For instance, in June 2019, terraplasma medical announced the launch of its new product along with CE approval for its cold plasma device for wound care applications. 

The accessories segment is set to rise at a CAGR of 15.8% in the coming years.

To know how our report can help streamline your business, Speak to Analyst

By Technology

Atmospheric Pressure Plasma Segment Dominated Market Due to Ease of Use in Clinical Settings 

Based on technology, the market is segregated into atmospheric pressure plasma jet, dielectric barrier discharge, and others.

The atmospheric pressure plasma jet segment held the leading market share in 2025. In 2026, the segment is expected to dominate with a 60.6% share as it is easy to operate at the bedside and does not require enclosed chambers or complex preparation. Moreover, hospitals and outpatient wound-care centers prefer portable devices that can be used quickly during routine dressing changes. This technology supports flexible and repeatable treatment, which suits chronic wound care schedules. In addition, increasing investments in this technology is also expected to have a positive impact on the segment growth. 

• For instance, in October 2025, BioLab Holdings, Inc. announced to invest a substantial amount in cold atmospheric plasma technology. Through these investments, the company plans to expand its customer base across multiple geographies.

The dielectric barrier discharge segment is predicted to surge at a CAGR of 12.1% over the projected period. 

By Application

Wound Healing Segment Accounted for Major Share Due to High Patient Volume and Considerable Wound Prevalence

On the basis of application, the market is divided into wound healing, infection control & sterilization, dermatology & aesthetic medicine, cancer, and other.

The wound healing captured the largest share of the market in 2025. In 2026, the segment is anticipated to dominate with a 57.2% share. Conditions such as diabetic foot ulcers, pressure sores, venous leg ulcers, and post-surgical wounds require repeated care over long periods, and cold plasma fits well into this continuous treatment approach. In addition, wound-care clinics and specialty centers increasingly look for supportive, non-invasive therapies that can help improve recovery timelines and reduce complications. Cold plasma can be used alongside standard wound dressings and cleaning routines, which makes it easy to adopt without replacing existing practices. 

• For instance, according to data published by the University of Wisconsin, an estimated 2 million Americans suffer from diabetic foot ulcer every year. 

The cancer segment is projected to increase at a CAGR of 13.5% during the forecast period.

By End-user

Hospitals & Specialty Clinics Segment Led Due to Structured Clinical Workflows and High Patient Preference

Based on end-user, the market is segmented into hospitals & specialty clinics, academic & research institutes, and others.

In 2025, the hospitals & specialty clinics segment dominated the global market. Hospitals and specialty clinics hold the major share as they handle the majority of chronic wound and dermatology cases. These settings have dedicated staff, treatment rooms, and procurement budgets, making them the primary adopters of new therapies. Cold plasma is commonly introduced here first before expanding to home-care and community settings. 

In addition, the academic & research institutes segment is projected to grow at a CAGR of 13.8% during the study period. 

Cold Plasma Market Regional Outlook

In terms of region, the market is divided into North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa. 

Europe

To get more information on the regional analysis of this market, Download Free sample

Europe dominated the global market in 2025. The European market is expected to register a CAGR of 12.5% and reach a valuation of USD 67.0 million by 2026, driven by the substantial adoption of cold plasma technology and the early launch of products. Supported by these factors, France, the U.K., and Germany are expected to reach valuations of USD 10.9 million, USD 15.2 million, and USD 8.9 million, respectively, in 2026. 

North America 

North America held a substantial share in 2024, valued at USD 46.5 million, and maintained its leading position in 2025, with USD 52.7 million. Certain factors, such as a focus on infection prevention, a substantial prevalence of wounds, and new product launches, are playing a vital role in maintaining a major market share. In 2026, the U.S. market is set to reach USD 56.2 million. Rising investments by market players to enhance technology and introduce new products are also estimated to drive market growth in the U.S.

• For instance, in July 2025, Adtec Healthcare Limited received funding of USD 12.0 to expand its cold plasma technology in the U.S. market. 

Asia Pacific

Asia Pacific is predicted to emerge as the fastest-growing region during the forecast period, with market projections indicating a value of USD 38.7 million in 2026. Country-level estimates show that India and China will contribute significantly, reaching USD 8.6 million and USD 12.9 million, respectively, by the end of 2026. 

Latin America and Middle East & Africa 

Latin America and Middle East & Africa are likely to record moderate expansion. The Latin America market is projected to reach USD 10.5 million in 2026, driven by strengthened healthcare systems and increased investments in high-quality medical infrastructure. Meanwhile, GGC within the Middle East & Africa region is projected to record a valuation of USD 2.5 million in 2026. 

COMPETITIVE LANDSCAPE

Key Industry Players

Clinical Accuracy, Connectivity, and Maternal Comfort to Help Companies Maintain Their Market Positions

The global cold plasma market is moderately consolidated, led by a handful of specialized European players and a growing U.S. entrant base. Activity is concentrated in chronic wound care and dermatology, with an emerging lane in surgical soft-tissue ablation. 

Key companies operating in the market include Neoplas Med, Adtec Healthcare, Terraplasma Medical, CINOGY, and US Medical Innovations, among others. The development of portable and technologically advanced devices is assisting companies in maintaining their market position. 

Other notable players include Coldplasmatech, Plasmacure, and regional partners such as Viromed and SG Biomedical, which support market education and distribution. These players are pursuing targeted strategies such as portable, nurse-friendly devices for outpatient wound centers, patch-based solutions that fit routine dressing changes, and simple digital record-keeping to help clinics track sessions and outcomes. 

LIST OF KEY COLD PLASMA COMPANIES PROFILED:

• terraplasma medical GmbH (Germany)
• ADTEC Plasma Technology Co., Ltd. (Japan)
• Relyon Plasma GmbH (Germany)
• Neoplas Tools GmbH (Germany)
• PlasmaMed GmbH (Germany)
• Noxilizer, Inc. (U.S.)
• Enercon Industries Corporation (U.S.)
• TOMI Environmental Solutions, Inc. (U.S.)
• Apyx Medical Corporation (U.S.)
• Europlasma NV (Belgium)

KEY INDUSTRY DEVELOPMENTS

• July 2025: Plasmacure B.V. raised USD 6.9 million through rounds of series funding. The funding will enable the company to expand its global product reach through strategic collaborations.
• December 2024: relyon plasma GmbH and Viromed Medical GmbH entered into a strategic collaboration to explore new application areas of cold plasma in medical. 
• October 2024: St. Antonius wound center received USD 2.1 million in funding to extend its research into Plasmacure wound therapy.
• June 2022: Niterra announced a strategic partnership & investment in Neoplas Med to expand cold-plasma wound care globally.
• April 2022: Adtec Plasma Technology Co., Ltd. announced the launch of its PlasmaTacta, a cold plasma device for antimicrobial applications. 

REPORT COVERAGE 

The global market analysis provides an in-depth study of market size and forecast by all the market segments included in the report. It includes details on the market dynamics and market trends expected to drive the market over the forecast period. It offers information on technological advancements, new product launches, key industry developments, and details on partnerships, mergers, and acquisitions. The market research report also encompasses detailed competitive landscape with information on the market share and profiles of key operating players.

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation